Daré Bioscience, Inc. (DARE)

Daré Bioscience Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	11.64	34.68	51.67	4.67	4.78
Cash & Cash Equivalents	11.64	34.68	51.67	4.67	4.78
Cash Growth	-66.44%	-32.89%	1006.64%	-2.31%	-29.77%
Receivables	0.95	1.7	1.15	0.46	0.56
Other Current Assets	4.95	6.66	2.48	1.85	1.11
Total Current Assets	17.54	43.04	55.3	6.98	6.44
Property, Plant & Equipment	1.98	0.52	0.03	0.04	0.06
Other Long-Term Assets	1.76	0.26	0.49	0.53	0.94
Total Long-Term Assets	3.74	0.79	0.51	0.57	1
Total Assets	21.28	43.83	55.81	7.55	7.44
Accounts Payable	3.39	2.03	2.1	1.02	1.08
Deferred Revenue	1	1	1	1	0
Current Debt	0.47	0.4	0.27	0.71	0.41
Other Current Liabilities	15.63	28.2	12.68	4.92	4.12
Total Current Liabilities	20.48	31.62	16.05	7.66	5.61
Long-Term Debt	0.94	0.09	0	0.04	0.39
Other Long-Term Liabilities	4.91	1	1	1	1
Total Long-Term Liabilities	5.85	1.09	1	1.04	1.39
Total Liabilities	26.33	32.71	17.05	8.7	7
Total Debt	1.4	0.49	0.27	0.76	0.8
Debt Growth	187.37%	80.65%	-64.25%	-5.45%	8142.74%
Retained Earnings	-171.24	-141.07	-110.13	-71.43	-44.02
Comprehensive Income	-0.36	-0.35	-0.15	-0.09	-0.1
Shareholders' Equity	-5.05	11.11	38.75	-1.15	0.44
Net Cash / Debt	10.24	34.19	51.4	3.91	3.98
Net Cash / Debt Growth	-70.07%	-33.48%	1213.79%	-1.68%	-41.44%
Net Cash Per Share	1.41	4.85	10.09	1.56	3.07
Working Capital	-2.94	11.41	39.24	-0.68	0.83
Book Value Per Share	-0.69	1.58	7.61	-0.46	0.34

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).